BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu T, Li Y, Lu W, Spitters T, Fang X, Wang J, Cai S, Gao J, Zhou Y, Duan Z, Xiong H, Liu L, Li Q, Jiang H, Chen K, Zhou H, Lin H, Feng H, Zhou B, Antos CL, Luo C. Discovery of a subtype-selective, covalent inhibitor against palmitoylation pocket of TEAD3. Acta Pharm Sin B 2021;11:3206-19. [PMID: 34729310 DOI: 10.1016/j.apsb.2021.04.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Lou J, Lu Y, Cheng J, Zhou F, Yan Z, Zhang D, Meng X, Zhao Y. A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities. European Journal of Medicinal Chemistry 2022;243:114684. [DOI: 10.1016/j.ejmech.2022.114684] [Reference Citation Analysis]
2 Luo M, Xu Y, Chen H, Wu Y, Pang A, Hu J, Dong X, Che J, Yang H. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers. European Journal of Medicinal Chemistry 2022;244:114847. [DOI: 10.1016/j.ejmech.2022.114847] [Reference Citation Analysis]
3 Lo Sardo F, Canu V, Maugeri-Saccà M, Strano S, Blandino G. YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. Biochim Biophys Acta Rev Cancer 2022;1877:188756. [PMID: 35777600 DOI: 10.1016/j.bbcan.2022.188756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Heinrich T, Peterson C, Schneider R, Garg S, Schwarz D, Gunera J, Seshire A, Kötzner L, Schlesiger S, Musil D, Schilke H, Doerfel B, Diehl P, Böpple P, Lemos AR, Sousa PMF, Freire F, Bandeiras TM, Carswell E, Pearson N, Sirohi S, Hooker M, Trivier E, Broome R, Balsiger A, Crowden A, Dillon C, Wienke D. Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106. J Med Chem 2022. [PMID: 35763499 DOI: 10.1021/acs.jmedchem.2c00403] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Liberelle M, Toulotte F, Renault N, Gelin M, Allemand F, Melnyk P, Guichou JF, Cotelle P. Toward the Design of Ligands Selective for the C-Terminal Domain of TEADs. J Med Chem 2022. [PMID: 35389210 DOI: 10.1021/acs.jmedchem.2c00075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond) 2022;136:197-222. [PMID: 35119068 DOI: 10.1042/CS20201474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
7 Li Y, Li Y, Ning C, Yue J, Zhang C, He X, Wang Y, Liu Z. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation. Computational Biology and Chemistry 2022. [DOI: 10.1016/j.compbiolchem.2022.107648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ye Z, Wang K, Chen L, Jin X, Chen H, Tang G, Yao SQ, Feng Z, Zhang CJ. A targeted covalent inhibitor of p97 with proteome-wide selectivity. Acta Pharm Sin B 2022;12:982-9. [PMID: 35256959 DOI: 10.1016/j.apsb.2021.09.003] [Reference Citation Analysis]
9 Liu L, Zhu R, Li J, Pei Y, Wang S, Xu P, Wang M, Wen Y, Zhang H, Du D, Ding H, Jiang H, Chen K, Zhou B, Yu L, Luo C. Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1). J Med Chem 2022. [PMID: 35089030 DOI: 10.1021/acs.jmedchem.1c01686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]